These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 24753447)

  • 1. Chiral resolution and pharmacological characterization of the enantiomers of the Hsp90 inhibitor 2-amino-7-[4-fluoro-2-(3-pyridyl)phenyl]-4-methyl-7,8-dihydro-6H-quinazolin-5-one oxime.
    Amici R; Bigogno C; Boggio R; Colombo A; Courtney SM; Dal Zuffo R; Dondio G; Fusar F; Gagliardi S; Minucci S; Molteni M; Montalbetti CA; Mortoni A; Varasi M; Vultaggio S; Mercurio C
    ChemMedChem; 2014 Jul; 9(7):1574-85. PubMed ID: 24753447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
    Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
    Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperone.
    Vallée F; Carrez C; Pilorge F; Dupuy A; Parent A; Bertin L; Thompson F; Ferrari P; Fassy F; Lamberton A; Thomas A; Arrebola R; Guerif S; Rohaut A; Certal V; Ruxer JM; Gouyon T; Delorme C; Jouanen A; Dumas J; Grépin C; Combeau C; Goulaouic H; Dereu N; Mikol V; Mailliet P; Minoux H
    J Med Chem; 2011 Oct; 54(20):7206-19. PubMed ID: 21972823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
    Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
    J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available heat shock protein 90 inhibitor in a human tumor xenograft mouse model.
    Yamazaki S; Nguyen L; Vekich S; Shen Z; Yin MJ; Mehta PP; Kung PP; Vicini P
    J Pharmacol Exp Ther; 2011 Sep; 338(3):964-73. PubMed ID: 21680888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of diamine-linked 17-aroylamido-17-demethoxygeldanamycins as potent Hsp90 inhibitors.
    Li Z; Jia L; Wang J; Wu X; Hao H; Wu Y; Xu H; Wang Z; Shi G; Lu C; Shen Y
    Eur J Med Chem; 2014 Nov; 87():346-63. PubMed ID: 25277067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and Evaluation of a Novel Deguelin Derivative, L80, which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90.
    Lee SC; Min HY; Choi H; Kim HS; Kim KC; Park SJ; Seong MA; Seo JH; Park HJ; Suh YG; Kim KW; Hong HS; Kim H; Lee MY; Lee J; Lee HY
    Mol Pharmacol; 2015 Aug; 88(2):245-55. PubMed ID: 25976766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.
    Bao R; Lai CJ; Qu H; Wang D; Yin L; Zifcak B; Atoyan R; Wang J; Samson M; Forrester J; DellaRocca S; Xu GX; Tao X; Zhai HX; Cai X; Qian C
    Clin Cancer Res; 2009 Jun; 15(12):4046-57. PubMed ID: 19509149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of novel macrocyclic 2-amino-6-arylpyrimidine Hsp90 inhibitors.
    Suda A; Koyano H; Hayase T; Hada K; Kawasaki K; Komiyama S; Hasegawa K; Fukami TA; Sato S; Miura T; Ono N; Yamazaki T; Saitoh R; Shimma N; Shiratori Y; Tsukuda T
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1136-41. PubMed ID: 22192591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isoxazolo(aza)naphthoquinones: a new class of cytotoxic Hsp90 inhibitors.
    Bargiotti A; Musso L; Dallavalle S; Merlini L; Gallo G; Ciacci A; Giannini G; Cabri W; Penco S; Vesci L; Castorina M; Milazzo FM; Cervoni ML; Barbarino M; Pisano C; Giommarelli C; Zuco V; De Cesare M; Zunino F
    Eur J Med Chem; 2012 Jul; 53():64-75. PubMed ID: 22538015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NMS-E973, a novel synthetic inhibitor of Hsp90 with activity against multiple models of drug resistance to targeted agents, including intracranial metastases.
    Fogliatto G; Gianellini L; Brasca MG; Casale E; Ballinari D; Ciomei M; Degrassi A; De Ponti A; Germani M; Guanci M; Paolucci M; Polucci P; Russo M; Sola F; Valsasina B; Visco C; Zuccotto F; Donati D; Felder E; Pesenti E; Galvani A; Mantegani S; Isacchi A
    Clin Cancer Res; 2013 Jul; 19(13):3520-32. PubMed ID: 23674492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the entry region of Hsp90's ATP binding pocket with a novel 6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl amide.
    Jeong JH; Oh YJ; Lho Y; Park SY; Liu KH; Ha E; Seo YH
    Eur J Med Chem; 2016 Nov; 124():1069-1080. PubMed ID: 27783977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereospecific antitumor activity of radicicol oxime derivatives.
    Soga S; Sharma SV; Shiotsu Y; Shimizu M; Tahara H; Yamaguchi K; Ikuina Y; Murakata C; Tamaoki T; Kurebayashi J; Schulte TW; Neckers LM; Akinaga S
    Cancer Chemother Pharmacol; 2001 Dec; 48(6):435-45. PubMed ID: 11800023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design.
    Miura T; Fukami TA; Hasegawa K; Ono N; Suda A; Shindo H; Yoon DO; Kim SJ; Na YJ; Aoki Y; Shimma N; Tsukuda T; Shiratori Y
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5778-83. PubMed ID: 21875802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of Her2/neu binding to Hsp90 by emodin azide methyl anthraquinone derivative induces proteasomal degradation of Her2/neu.
    Yan YY; Zheng LS; Zhang X; Chen LK; Singh S; Wang F; Zhang JY; Liang YJ; Dai CL; Gu LQ; Zeng MS; Talele TT; Chen ZS; Fu LW
    Mol Pharm; 2011 Oct; 8(5):1687-97. PubMed ID: 21812426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of NMS-E973 as novel, selective and potent inhibitor of heat shock protein 90 (Hsp90).
    Brasca MG; Mantegani S; Amboldi N; Bindi S; Caronni D; Casale E; Ceccarelli W; Colombo N; De Ponti A; Donati D; Ermoli A; Fachin G; Felder ER; Ferguson RD; Fiorelli C; Guanci M; Isacchi A; Pesenti E; Polucci P; Riceputi L; Sola F; Visco C; Zuccotto F; Fogliatto G
    Bioorg Med Chem; 2013 Nov; 21(22):7047-63. PubMed ID: 24100158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fragment-based identification of Hsp90 inhibitors.
    Barker JJ; Barker O; Boggio R; Chauhan V; Cheng RK; Corden V; Courtney SM; Edwards N; Falque VM; Fusar F; Gardiner M; Hamelin EM; Hesterkamp T; Ichihara O; Jones RS; Mather O; Mercurio C; Minucci S; Montalbetti CA; Müller A; Patel D; Phillips BG; Varasi M; Whittaker M; Winkler D; Yarnold CJ
    ChemMedChem; 2009 Jun; 4(6):963-6. PubMed ID: 19301319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model.
    Zapf CW; Bloom JD; Li Z; Dushin RG; Nittoli T; Otteng M; Nikitenko A; Golas JM; Liu H; Lucas J; Boschelli F; Vogan E; Olland A; Johnson M; Levin JI
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4602-7. PubMed ID: 21715165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of 2-amino-6-(1H,3H-benzo[de]isochromen-6-yl)-1,3,5-triazines as novel Hsp90 inhibitors.
    Suda A; Kawasaki K; Komiyama S; Isshiki Y; Yoon DO; Kim SJ; Na YJ; Hasegawa K; Fukami TA; Sato S; Miura T; Ono N; Yamazaki T; Saitoh R; Shimma N; Shiratori Y; Tsukuda T
    Bioorg Med Chem; 2014 Jan; 22(2):892-905. PubMed ID: 24369839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of 3-Ethyl-4-(3-isopropyl-4-(4-(1-methyl-1 H-pyrazol-4-yl)-1 H-imidazol-1-yl)-1 H-pyrazolo[3,4- b]pyridin-1-yl)benzamide (TAS-116) as a Potent, Selective, and Orally Available HSP90 Inhibitor.
    Uno T; Kawai Y; Yamashita S; Oshiumi H; Yoshimura C; Mizutani T; Suzuki T; Chong KT; Shigeno K; Ohkubo M; Kodama Y; Muraoka H; Funabashi K; Takahashi K; Ohkubo S; Kitade M
    J Med Chem; 2019 Jan; 62(2):531-551. PubMed ID: 30525599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.